Endocrine Abstracts

Background: Graves orbitopathy (GO) is the most frequent and feared complication of Graves’ disease. In moderate-severe cases, intravenous (iv) glucocorticoids (GC) is the first-line treatment while Rituximab (RTX) is recommended as second-line treatment in patients non-responsive to GC. But data is scarce and contradictory.Objective: To investigate if patients with GO and poor response to iv GC benefit from a switch to RTX early in the treatment co...